The Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncology Research (GENyO) is holding the first course of the NanoCARE 2.0 Network at its facilities, a course where current techniques for the preclinical characterisation of nanomaterials have been discussed.

The NanoCARE 2.0. Thematic Network is a collaborative initiative focused on the development of nanomedicine to address specific challenges in the diagnosis and treatment of pathologies of high societal impact such as cancer, neurodegenerative diseases and infectious diseases with the ultimate goal of promoting clinical translation and entrepreneurship. The network brings together 15 multidisciplinary research groups spanning diverse scientific disciplines, including materials for biomedicine, pharmacology, chemistry, physics, biotechnology, microbiology or medicine. Among the groups mentioned is GENyO’s NanoChembio, which is led by Dr. Rosario Sánchez.

Dr. Sánchez is in charge of coordinating this network (RED2022-134560-T), which is funded by the State Research Agency and the Ministry of Science, Innovation and Universities (MCIN/AEI /10.13039/501100011033).

NanoCARE 2.0. aims to promote seed projects among the members of the network, facilitating the establishment of new collaborations and the strengthening of existing ones. This will allow a more solid submission to international calls for proposals and will lead to the emergence of new common lines of research, thus increasing the interdisciplinarity and international impact of Spanish nanomedicine.

On 13 February, the GENYO centre hosted the first Nanomedicine course organised by this Network. This course is focused on learning and discussing current techniques for preclinical characterisation of nanomaterials, as well as sharing professional advice in the field of nanomedicine.

For more information on the NanoCARE 2.0. network, please visit https://nanocare.es/.

See more news